Should we be surprised at the paucity of response to EGFR inhibitors?

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) signaling is crucial in cell growth and cancer.
• EGFR inhibitors are a key therapeutic class, but their efficacy varies significantly.
• Current methods to predict response to EGFR inhibitors are insufficient.

Purpose of the Study:

• To investigate the reasons for the poor correlation between EGFR expression and therapeutic response.
• To evaluate the role of assay limitations versus fundamental biological issues in EGFR inhibitor efficacy.
• To highlight the need for a deeper understanding of EGFR function in normal physiology and disease.

Main Methods:

• Review of existing data on EGFR function, signaling, and expression.
• Critical assessment of quantitative techniques, including immunohistochemistry.
• Revisiting early findings in EGFR biology.

Main Results:

• Current understanding and measurement of EGFR expression do not reliably predict response to EGFR inhibitors.
• Limitations in current assays may contribute to the poor correlation.
• Fundamental aspects of in-vivo EGFR function might be underestimated.

Conclusions:

• There is a significant gap in predicting therapeutic outcomes for EGFR inhibitors.
• Improved assays and a more comprehensive understanding of EGFR biology are essential for optimizing cancer therapy.
• Further research into EGFR ligands and binding partners is warranted.